Blueprint Medicines Corporation
BPMC
$88.48
-$0.03-0.03%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 54.96% | 57.91% | 62.35% | 168.80% | 30.09% |
| Total Depreciation and Amortization | 161.33% | 34.51% | 1.09% | 30.56% | -78.18% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 33.29% | -0.33% | -6.37% | -619.01% | -45.11% |
| Change in Net Operating Assets | -197.44% | 420.32% | 4.54% | -63.52% | 264.99% |
| Cash from Operations | 62.80% | 86.95% | 63.16% | 17.44% | 34.99% |
| Capital Expenditure | 80.06% | 99.60% | -0.59% | 57.28% | -215.53% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -58.48% | 998.83% | -636.46% | -55.39% | 261.08% |
| Cash from Investing | -57.21% | 412.45% | -687.20% | -55.36% | 247.83% |
| Total Debt Issued | 100.00% | -100.00% | -- | -- | -218.18% |
| Total Debt Repaid | 100.00% | -- | -- | -- | -- |
| Issuance of Common Stock | -37.47% | 4,163.81% | 489.11% | -- | 521.79% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -37.15% | -81.32% | 3,259.98% | -- | 523.36% |
| Foreign Exchange rate Adjustments | -371.87% | 209.24% | -152.54% | -173.60% | 1.88% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -19.40% | 317.64% | 37.26% | -15.17% | 109.23% |